论文部分内容阅读
地夫可特(deflazacort)是由意大利Laboratori Guidotti S.p.A.公司于1985年研发的一种口服药物,用于治疗过敏性哮喘、类风湿性关节炎、皮肤过敏等。2017年2月美国FDA批准地夫可特用于治疗杜氏肌营养不良症(duchenne muscular dystrophy,DM D)。这是全球获批的用于治疗DMD的首个皮质固醇类激素药物。地夫可特的商品名为Emflaza,该药通过减少炎症和降低免疫系统的活性起作用[1]。地夫可特的中文化学名:11β,21-二羟基-2’-甲基-5’-βH-
Deflazacort is an oral medication developed by Laboratori Guidotti S.p.A. of Italy in 1985 for the treatment of allergic asthma, rheumatoid arthritis, skin irritation and the like. February 2017 FDA approves delfac for use in the treatment of duchenne muscular dystrophy (DM D). This is the world’s first corticosteroid drug approved for the treatment of DMD. Defectives are marketed as Emflaza, which works by reducing inflammation and reducing immune system activity [1]. Dexter’s Chinese chemical name: 11β, 21-dihydroxy-2’-methyl-5’-βH-